And Finally … Rounding Out Our Top 10: Additional notable 2016 studies
Cardiovascular Outcomes with Newer Antidiabetes Drugs
Does CPAP Prevent Adverse CV Events in Patients with Obstructive Sleep Apnea?
Editor: Kirsten E. Fleischmann
Focus on Inappropriate Opioid Use Intensifies
Editor: Thomas L. Schwenk
New Sepsis-3 Definitions Await Confirmatory Data
Pulmonary Embolism as a Cause of Syncope
Racial Differences Persist in End-of-Life Care
Randomized Comparison of Surgery, Radiotherapy, and Surveillance for Prostate Cancer
With Oxygen, Could Less Be More?
Editor: Abigail Zuger, MD
Empagliflozin Is Associated with Fewer Adverse Renal Outcomes Voltar
Editor Associado: Allan S. Brett
Cardiovascular Outcomes with Newer Antidiabetes Drugs - Editor: Paul S. Mueller
| Artigo |
Autor(es) |
Referência |
|
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
|
Wanner Christoph, Inzucchi Silvio E, Lachin John M, Fitchett David, von Eynatten Maximilian, Mattheus Michaela, Johansen Odd Erik, Woerle Hans J, Broedl Uli C, Zinman Bernard,
|
The New England journal of medicine. 2016 Jul; 375(Jul):323-34. doi: 10.1056/NEJMoa1515920. pii: .
|
Nenhuma revista foi definida para este congresso.